Vision Loss Drug Vabysmo Secures English Funding; Oxlumo & Tavneos Deemed Too Pricey
Executive Summary
Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.
You may also be interested in...
‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount
Health technology assessment institute NICE has reversed its provisional rejection of Oxlumo for treating the rare disease, primary hyperoxaluria type 1.
Scotland Says No To Novartis’ Piqray
Scotland’s health technology assessment body, the SMC, has rejected Novartis’ targeted breast cancer drug Piqray, but accepted Lilly’s Verzenio, also for breast cancer.
First-Of-Kind Treatments Win Funding in England & Wales
Treatments for non-small cell lung cancer, Pompe disease and two main forms of ANCA-associated vasculitis from Roche, Sanofi and CSL Vifor respectively are to be made available for patients on the National Health Service.